Chicago Partners Investment Group buys $743,862 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Chicago Partners Investment Group scooped up 1,294 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 6,536 shares of Celgene Corporation which is valued at $743,862.Celgene Corporation makes up approximately 0.35% of Chicago Partners Investment Group’s portfolio.

Other Hedge Funds, Including , Boston Private Wealth reduced its stake in CELG by selling 12,558 shares or 5.19% in the most recent quarter. The Hedge Fund company now holds 229,465 shares of CELG which is valued at $26,650,065. Celgene Corporation makes up approx 1.06% of Boston Private Wealth’s portfolio.Carmignac Gestion boosted its stake in CELG in the latest quarter, The investment management firm added 2,127,659 additional shares and now holds a total of 9,708,359 shares of Celgene Corporation which is valued at $1,049,570,691. Celgene Corporation makes up approx 8.56% of Carmignac Gestion’s portfolio.Skylands Capital boosted its stake in CELG in the latest quarter, The investment management firm added 11,075 additional shares and now holds a total of 39,475 shares of Celgene Corporation which is valued at $4,267,642. Celgene Corporation makes up approx 0.66% of Skylands Capital’s portfolio.Cibc World Markets boosted its stake in CELG in the latest quarter, The investment management firm added 54,682 additional shares and now holds a total of 64,822 shares of Celgene Corporation which is valued at $6,969,661. Celgene Corporation makes up approx 0.03% of Cibc World Markets’s portfolio.

Celgene Corporation opened for trading at $113.84 and hit $114.8 on the upside on Monday, eventually ending the session at $114.62, with a gain of 1.08% or 1.23 points. The heightened volatility saw the trading volume jump to 29,78,509 shares. Company has a market cap of $88,844 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *